Health Care • Biotechnology: Pharmaceutical Preparations
$19.23 ▼ -0.09
(-0.47%)
MKT CAP: $2.03B • VOL: 1.19M
52W L $15 52W H $25
SRPT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.86B | $1.79B | $1.14B |
| YoY Revenue Growth % | +4.3% | +56.2% | — |
| Gross Profit | $1.84B | — | — |
| Gross Margin % | 98.0% | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$699.8M | $218.1M | -$267.8M |
| Operating Margin % | -37.5% | 12.2% | -23.4% |
| Net Income (GAAP) | -$713.4M | $235.2M | -$536.0M |
| EBITDA (Normalized) | -$618.2M | $327.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$205.5M | -$205.8M | -$501.0M |
| Capital Expenditures (CapEx) | $102.0M | $137.0M | — |
| Free Cash Flow (FCF) | -$307.5M | -$342.7M | -$501.0M |
| FCF Margin % | -16.5% | -19.2% | -43.8% |
| Return on Invested Capital (ROIC %) | -45.0% | 40.6% | — |
| Cash & Short-Term Equivalents | $801.3M | $1.10B | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $1.14B | $1.53B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SRPT.